Horichi N, Tapiero H, Sugimoto Y, Bungo M, Nishiyama M, Fourcade A, Lampidis T J, Kasahara K, Sasaki Y, Takahashi T
Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.
Cancer Res. 1990 Aug 1;50(15):4698-701.
The mechanism of action of 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) was examined in a human leukemia cell line (K562) and its Adriamycin (ADM)-resistant subline (K562/ADM). ADM and MX2 showed an equivalent antitumor effect against K562. K562/ADM was highly resistant to ADM. In cellular pharmacokinetic studies, MX2 showed faster and greater influx than did ADM in both K562 and K562/ADM. The efflux of ADM was rapid in K562/ADM but not in K562. On the other hand, the efflux of MX2 was rapid in both cell lines. The formation of DNA single-strand breaks and double-strand breaks by ADM was significantly lower in K562/ADM than K562. On the other hand, formation of those breaks by MX2 was not decreased. Although some of the DNA breaks induced by MX2 were resealed, there was no difference in the degree of resealing in K562 and K562/ADM cells. On the other hand, most of the small number of DNA breaks in K562/ADM induced by ADM were resealed. The topoisomerase II activity in K562 and K562/ADM was not significantly different. It is concluded that MX2 conquers multidrug resistance by rapid influx following a higher frequency of formation of DNA single- and double-strand breaks in K562/ADM cells.
在人白血病细胞系(K562)及其阿霉素(ADM)耐药亚系(K562/ADM)中研究了3'-脱氨基-3'-吗啉代-13-脱氧-10-羟基柔红霉素(MX2)的作用机制。ADM和MX2对K562显示出等效的抗肿瘤作用。K562/ADM对ADM高度耐药。在细胞药代动力学研究中,MX2在K562和K562/ADM中均显示出比ADM更快且更大的内流。ADM在K562/ADM中的外流很快,但在K562中则不然。另一方面,MX2在两种细胞系中的外流都很快。K562/ADM中ADM诱导的DNA单链断裂和双链断裂的形成明显低于K562。另一方面,MX2诱导的这些断裂的形成没有减少。尽管MX2诱导的一些DNA断裂被重新封闭,但K562和K562/ADM细胞中的重新封闭程度没有差异。另一方面,ADM在K562/ADM中诱导的少量DNA断裂大部分被重新封闭。K562和K562/ADM中的拓扑异构酶II活性没有显著差异。得出的结论是,MX2通过在K562/ADM细胞中以更高频率形成DNA单链和双链断裂后快速内流来克服多药耐药性。